KPV — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: α-MSH C-terminal tripeptide
Reported half-life: Short — minutes in plasma
Routes used in the literature: Oral, intraperitoneal and topical in published animal work
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Mouse colitis models (oral / drinking water)

Reported quantity: Around 100 µM in drinking water, or 10 µg/kg intraperitoneally
Frequency: Continuous (water) or once daily (injected)
Study duration: 5–14 days across the DSS-colitis literature

Nanoparticle-delivered arms report effect at substantially lower quantities.

In-vitro inflammatory signalling

Reported quantity: 1 µM to 100 µM in culture media
Frequency: Single exposure
Study duration: 4–24 hours

NF-κB translocation and cytokine output are the standard readouts.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

KPV · 10 mg Vial

KPV is dosed at 200 mcg–500 mcg daily via subcutaneous injection in educational protocols, often used in short anti-inflammatory cycles. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
Typical daily range: 200–500 mcg once daily (gradual titration recommended).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid freeze–thaw cycles.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Week 1	200 mcg	6 units (0.06 mL)
Week 2	300 mcg	9 units (0.09 mL)
Week 3	400 mcg	12 units (0.12 mL)
Weeks 4–8	500 mcg	15 units (0.15 mL)

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size KPV is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

KPV · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	200 mcg =	500 mcg =
10 mg	3.33 mg/ml	33 mcg	6.0 units	15 units

Unit columns use the range reported for this compound (200 mcg–500 mcg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

KPV is a small, highly soluble tripeptide. A 10 mg vial in 5 mL of bacteriostatic water gives 2 mg/mL.

Open the reconstitution calculator

How to read these figures

Molar figures (µM) dominate this literature rather than mass per body weight — conversion needs the 342 g/mol molecular weight.
Oral and injected arms are not equivalent; the colitis work exploits direct gut contact.
Tripeptides are cheap to synthesise and correspondingly easy to under-fill — check peptide content, not vial mass.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. · Gastroenterology · 2008 · PMID 18061177
Mice with colitis received oral or intracolonic KPV tripeptide administration to assess PepT1-mediated reduction of intestinal inflammation.
View the record
[2]
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Kannengiesser K, Maaser C, Heidemann J, et al. · Inflammatory Bowel Diseases · 2008 · PMID 18092346
Mice with experimental colitis received intraperitoneal or intrarectal KPV tripeptide to evaluate dose-dependent anti-inflammatory effects.
View the record
[3]
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Xiao B, Xu Z, Viennois E, et al. · Molecular Therapy · 2017 · PMID 28143741
Mice with ulcerative colitis received orally administered KPV encapsulated in hyaluronic acid nanoparticles daily to assess reduction in colonic inflammation.
View the record

Search the databases yourself

Read the KPV research brief

Other immune compounds

AdamaxCyclic Semax analogue (cyclo-prolylglycine related)LL-3737-amino-acid cathelicidin antimicrobial peptide ThymalinThymic peptide extract preparation Thymosin Alpha-128-amino-acid thymic peptide

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.